Vyvgart and Vyvgart Hytrulo expanded for generalized myasthenia gravis

What this means

Vyvgart and Vyvgart Hytrulo are antibody-based treatments that lower harmful antibodies in the blood by blocking a protein that normally recycles them, helping to ease muscle weakness in myasthenia gravis. Today FDA expanded the approval of both drugs to cover all adults with generalized myasthenia gravis, regardless of their specific antibody status. This decision could offer more patients access to a treatment that targets the underlying cause of their symptoms.